Form 4: Tandem Diabetes Care Director Increases Common Stock Holdings and Receives New Equity Award

Rebecca B. Robertson, a Director at Tandem Diabetes Care Inc., reported an increase in her direct common stock ownership following the conversion of restricted stock units and the grant of new equity awards.

Summary

• Rebecca B. Robertson, a Director of Tandem Diabetes Care Inc. (TNDM), reported changes in her beneficial ownership of company securities.
• On May 22, 2025, Ms. Robertson acquired 4,387 shares of common stock at a price of $20.64 per share, resulting from the exercise/conversion of previously awarded restricted stock units (RSUs).
• These 4,387 RSUs were originally awarded on May 22, 2024, under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan and vested on their one-year anniversary.
• Following this transaction, Ms. Robertson directly owns 13,783 shares of Tandem Diabetes Care common stock.
• Additionally, on May 21, 2025, Ms. Robertson was awarded 8,759 new restricted stock units (RSUs) under the 2023 Plan.
• Each RSU represents a contingent right to receive one share of common stock or cash, vesting on the one-year anniversary of the grant date (May 21, 2026).
• After these transactions, Ms. Robertson beneficially owns 8,759 unvested restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their direct ownership of common stock and receiving new equity awards, indicating continued alignment with shareholder interests and confidence in the company's long-term prospects.

Positives

• The Director's direct ownership of common stock increased to 13,783 shares, aligning her interests more closely with shareholders.
• The grant of 8,759 new restricted stock units demonstrates continued equity-based compensation and long-term incentive for the Director, reinforcing commitment to the company's future performance.

Future Outlook

The newly granted 8,759 restricted stock units are scheduled to vest on the one-year anniversary of their grant date, May 21, 2026, subject to the terms of the 2023 Long-Term Incentive Plan.

Industry Context

This filing is a routine disclosure of insider stock transactions, common across all publicly traded companies, and does not directly reflect broader industry trends in the diabetes care sector. It primarily indicates internal compensation and ownership changes.

Corporate Governance

Stakeholder Impact

• Shareholders: The increase in a director's direct common stock ownership and the grant of new equity awards can be viewed positively, as it enhances alignment between management and shareholder interests, potentially signaling confidence in the company's future.

Next Steps

• The 8,759 restricted stock units granted on May 21, 2025, are expected to vest on May 21, 2026, converting into common stock or cash per the 2023 Plan.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Unit, RSU, Director Compensation, Equity Award